Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) have their first approved therapy, UCB's Kygevvi, after the European Commission cleared the drug "under exceptional ...

AI company Anthropic has launched a new large language model (LLM) – Claude Fable 5 – claiming its capabilities as a tool for drug discovery and scientific research gives it a big lead over other ...

The Danish Group stated that the new corporate culture – dubbed 'The Novo Way' – centres around four Cs; namely, customer ...

Etcamah is already approved in the US, Europe, and other markets for use in combination with a CDK4/6 inhibitor as a ...

GSK reported good clinical trial results with two of its lung cancer therapies – Jideytro and risvutatug rezetecan (ris-rez) ...

The offer is legally conditioned upon the private equity company's Respighi BidCo vehicle securing at least a two-thirds ...

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes (T1D). The EMA's human ...

Hard on the heels of a big disappointment in its cardiovascular pipeline, Novartis has suffered another – this time for its highly anticipated neuromuscular disease therapy del-desiran. The company's ...

There's been a lot of talk about forging closer ties between Europe and Canada in response to the US' aggressive disruption of international trade. Now, two senior figures in Canada's life sciences ...

Roche is preparing to file one BTK-targeting drug for approval, and has just added another with potential across oncology, immunology, and neurology via a deal with Nurix Therapeutics. The licensing ...

Gilead's twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV, lenacapavir, will not be routinely funded by the ...

Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low ...